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SUMMARY
Fetal bone marrow liver and spleen of gestational age 15-20 weeks contain CALLA+,
HLA-DR+ lymphoid cells. We show that a proportion of them expresses surface
membrane immunoglobulins (SIg) as well as B cell differentiation antigens. A multiple
phenotypic analysis reveals that CALLA+ fetal B cells are: HLA-DR+, SIg+, FMC8+,
BAI +, Y29.55+ or Y29.55-, B2+, TdT-. Tissue specific phenotypic differences concern
the expression of B7 and HLA-DC on spleen but not on bone marrow B cells. This study
indicates that the distribution of the CALL antigen across the B cell committed lineage is
much wider in fetal than neonatal life since CALLA+ B cells have not yet been detected in
bone marrow and peripheral blood of normal infants and adults. In addition, the
interpretation of our phenotypic data suggest that fetal bone marrow B cells are more
immature than those present in the spleen, thus, further supporting the evidence that the
bone marrow is the organ of B cell lymphopoiesis.
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INTRODUCTION
The common acute lymphoblastic leukaemia (CALLA) antigen is a non-phosphorilated surface
membrane glycoprotein ofmol. wt 100,000 (Newman, Sutherland & Greaves, 1981), whose cellular
distribution among normal and malignant hemopoietic tissues has been serologically characterized
by the use of xenoantisera (Greaves et al., 1980; Janossy & Greaves, 1978), and monoclonal
antibodies (MoAb) such as J5 (Ritz et al., 1980), and ViL-Al (Knapp et al., 1982). Thus, in
haemoproliferative diseases CALLA is expressed in the majority of non-T, non-B lymphoblastic
leukaemias and in some T-ALL (Greaves et al., 1983), in Burkitt's lymphomas and some B-NHLs
(Ritz et al., 1981; Delia et al., 1984). CALLA+ haemopoietic cells are found in discrete amounts in
fetal tissues such as liver and bone marrow (Hokland et al., 1983), and in bone marrows from
healthy children (Greaves et al., 1980). Non-haemopoietic tissues can also express CALLA
(Metzgar et al., 1981). CALLA+ leukaemic cells and their normal counterparts carry HLA-DR
molecules, the nuclear enzyme terminal deoxynucleotidyl transferase (TdT) and are devoid of
surface immunoglobulins though can exhibit cytoplasmic IgM (Janossy et al., 1979).
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The finding that CALLA+ leukaemias have rearranged immunoglobulin genes (Korsmeyer et
al., 1981), has unequivocally shown that they are committed B cell precursors. The observation that
mature B cell neoplasias such as Burkitt's and non-Hodgkin lymphomas which are strongly positive
for SmIg can be CALLA+ suggests that this antigen has a wider distribution along the lymphoid
maturation pathway than it was originally thought. Alternatively these B cell tumours could
aberrantly express CALLA.
In this report we show that a proportion of B cells from fetal haemopoietic tissues are
unexpectedly CALLA+, this finding contrasts with what is observed in infants and adults where
bone marrow B cells are CALLA-, and may rule out the possibility that CALLA+ B cell
malignancies arise from an aberrant gene expression of this antigen.
MATERIALS AND METHODS
Preparation of cell suspensions from fetal tissues. Fetal tissues were obtained from cases
undergoing abortions carried out at the Gynaecological Clinic of Milan University by dilatation
and evacuation. The age of the fetuses was determined by the use of ultrasounds. Cell suspensions
from livers and spleens were obtained by finely mincing the specimens with a scalpel and by
pipetting the small clumps several times. Bone marrow cells were obtained by flushing with a syringe
RPMI 1640 (GIBCO, UK) into the intramedullary cavities of femoral bones. All cell suspensions
were subjected to Ficoll-Hypaque density gradient separations; the interphase cells were recovered,
washed twice and used for the immunofluorescence (IF) staining.
Antibodies. The MoAb used in this study are listed in Table I together with their specificity and
references. Their binding to the cells was detected by IF using a fluorescein isothiocyanate (FITC)
conjugated Fab2 fragment of a goat anti-mouse. Fluorescein and rhodamine-labelled Fab2
xenoantisera directed against surface immunoglobulins were the following: goat anti-Ig total, goat
anti-IgM, goat anti-IgD, burro anti-K and burro anti-A', all obtained from Kallestad (Austin, Texas,
USA). The nuclear enzyme TdT was detected by IF on methanol fixed cytocentrifuge preparations
as previously described, Bollum (1979), using a rabbit anti-TdT (BRL, Rockville, Maryland, USA)
followed by a rhodamine conjugated swine anti-rabbit (Nordic, The Netherlands). Normal mouse
and normal rabbit sera were always included as negative controls for the murine MoAb antibodies
and for the TdT determinations. All the antibodies were used at saturating concentrations, as
previously determined. IF was evaluated by fluorescence microscope (Zeiss epi-illumination) and
by fluorescence activated cell sorter (FACS IV, Becton-Dickinson, Mountain View, California,
USA).
FACS separation and relabelling of SIg+ cells. Cells from fetal tissues were sorted out by the
FACS on the basis of their reactivity with the Fab2 goat anti-human Ig. Prior to restaining with the
relevant MoAb, the collected SIg+ fraction was exposed to a diffuse laser light (wavelength 488 nm)
in order to quench the fluorescence of the fluorochrome (this treatment, carried out at 4 JC, had no
Table 1. List of MoAb used in this study
Antibody Specificity References
Vil-Al GP 100 Kd CALL Knapp et al. 1982
FMC8 B Subset+ C-ALL Brooks et al. 1982
OKB2 pan B Mittler et al. 1983
OKB7 pan B Mittler et al. 1983
BA1 pan B Abramson et al. 1981
Y29.55 Early B+B Subset Forster et al. 1982
DA2 HLA-DR monomorphic Brodsky et al. 1979
TU22 HLA-DC monomorphic Ziegler et al. 1981
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effect on the cell viability). Quenching was checked by fluorescence microscopy and by FACS
analysis. The cells were then relabelled by incubation with the specific monoclonal antibody or with
irrelevant mouse Igs for the negative control, followed by another incubation with the fluorescein
conjugated Fab2 goat anti-mouse. The analysis was carried out with the FACS.
Dual immunofluorescence staining procedure. The simultaneous expression of SIg and anyone of
the various cell-surface antigens was detected by the combination of fluorescein and rhodamine-
labelled reagents.The staining sequence was the following: after incubation with the relevant MoAb
(or normal mouse Ig for the negative control), the cells were washed twice in RPMI plus 2% FCS,
and incubated with a rhodamine labelled Fab2 goat anti-mouse. Following two more washes, the
cells were incubated with the fluorescein labelled Fab2 goat anti-human Ig. After two further
washes, the double IF was evaluated by fluorescence microscopy. All incubations were carried out
at 4 C for 20 min.
RESULTS
Composite phenotype offetal tissue cell suspensions
Fifteen specimens (seven livers, five spleens, three bone marrows) were included in this study and the
results are listed in Table 2. CALLA+ cells, detected with Vil-Al, were consistently present in all
specimens, with bone marrow containing a large number (> 20%), HLA-DR determinants were
expressed in liver (- 12%) spleen ( - 32%) and bone marrow (- 68%) whereas the DC determinants
were strongly detected in spleen and only occasionally in bone marrow; in this latter case the cells
were dimly stained. B2, FMC8 and BAl stained approximately a similar percentage of cells in the
three tissues, with bone marrows containing a large number of positive cells, many of which of
myeloid morphology (as judged by the phase contrast microscopic readings). Y29.55+ cells were
detected in all specimens and, similarly to the three previous markers, it also stained bone marrow
myeloid cells. SIg+ cells expressing the IgM and IgD isotypes were largely present in the spleen
(> 26%) followed by the bone marrow (< 12 %) and by the liver ( < 6%). Spleen SIg+ cells exhibited
an extremely bright fluorescence in contrast to the dimly stained bone marrow and liver cells. K and
i light chains were also detected and for each specimen the sum of their percentages never exceeded
that of SIg; it actually tended to be lower.
Multiphenotypic analysis of the SIg+ cells
The data obtained from the study carried out on the FACS-enriched SIg+ fractions are shown in
Table 3. It can be seen that 100 per cent of the SIg+ cells were HLA-DR+, B2+, BAl +. The majority
of bone marrow and liver B cells were CALLA+; fewer cells expressed the CALL antigen in the
spleen. FMC8 and Y29.55 stained 100% of bone marrow B cells; the former gave similar reactivity
in the liver, the latter gave variable reactivity in the liver and spleen specimens ranging from 50 to
100%. The markers that gave strong differential binding were TU22 (anti-HLA-DC) and B7. Their
reactivity was in fact restricted to the spleen, though they both displayed a weak reactivity with a
small percentage of the bone marrow SIg+ cells (see Fig. 1). Irrelevant mouse Ig, included to
evaluate the non-specific cross-reactivity between the various antibodies gave consistently negative
results.
Nuclear TdT versus other cell surface markers
Double staining for TdT and cell surface antigens was performed on bone marrow and liver
specimens (see Table 4), but not on spleen since we had previously found that this latter contains less
than 1/1,000 TdT+ cells. TdT+ mononuclear cells ranged between 5 and 13% in the bone marrow
and 1 and 6% in liver. In the bone marrow 80% of the TdT+ cells were CALLA+ and in the liver
100% of the TdT+ were CALLA+. About 94% of the TdT+ bone marrow cells were positive for
FMC8; in liver only 68% of the TdT+ cells expressed the FMC8 determinant. TdT+ cells from bone
marrows and livers were 100% positive for BA 1. No TdT + bone marrow or liver cells were positive
for Y29.55 or SIg.
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Table 3. Phenotype of the FACS separated SIg+ fractions
Specimen CALLA HLA-DR HLA-DC B2 B7 FMC8 BAl Y29.55 NMS
Liver 75-100 100 nt 100 0 100 100 50-100 0
Spleen 25-58 100 90-100* 100 100 75-100 100 80-100 0
Bone marrow 65-100 100 10-20* 100 10 100 100 100 0
Cell sorting and phenotype of the SIg+ cells was carried out as described in Materials and
Methods. The purity of the sorted fractions was always > 95%. At least three specimens of
each tissue were tested and results are expressed in percentage of positive cells. NMS is an
irrelevant mouse Ig, included to measure the non-specific binding of the reagents.
nt = not tested
* TU22 gave a strong binding with spleen B cells and a very weak one with a small
proportion of bone marrow B cells, with average fluorescence intensities (as measured by the
FACS) of 100 and > 255, respectively.
Fig. 1. Simultaneous detection of SIg, HLA-DR and DC by FACS analysis and tridimensional display. SIg and
DR or DC determinants were detected with the use of fluorescein and phycoerythrin-labelled reagents,
respectively. The staining sequence was the following: the cells were first incubated with DA2 or TU22 MoAb,
then with a biotynilated horse anti-mouse (1:50) (Vector Labs, California) followed by an incubation with
avidin conjugated phycoerythrin (Becton-Dickinson, California) and finally with a Fab2 goat anti-human
Ig-FITC. The double immunofluorescence was evaluated by the FACS equipped with a 600 LP and 520 LP plus
540 SP interference filters (Ditric Optics, Massachusetts, USA) for the detection of the red and green
fluorescencies, respectively. Excitation wavelength: 501 nm. Negative controls were used to determine the
non-specific cross-reactivity of the reagents (which was consistently low) and to set up the instrument. In this
particular experiment positivities for HLA-DR, HLA-DC and SIg were 40, 39 and 41%, respectively; for the
spleen and bone marrow 46, 1 and 14%, respectively.
Domenico Delia et al.
DISCUSSION
Lymphocytes bearing surface Ig can be detected, during lymphopoiesis, from 9 weeks gestation
onwards, Asma et al. (1977) and from 10 to 12 weeks can synthesize IgM stimulation, Gitlin &
Biasucci (I1969). Though we have not investigated this latter point, our data confirm the presence, in
fetuses of 15-20 weeks gestation age, of SIg+ cells, which, in addition, have B cell lineage, multiple
phenotypic markers. Morphologically, these cells appear as small lymphocytes in bone marrow and
liver and medium size lymphocytes in spleen (see Fig. 2). Our data are also in agreement with
previous reports on the presence of CALLA+ lymphoid cells in fetal tissues (Hokland et al., 1983).
By extending the study on the nature of such CALLA+ fetal cells we found that a percentage of
them bear surface immunoglobulins. Cell separations and dual IF studies have unequivocally
shown that the SIg+ cells are HLA-DR+, BAl +, B2+ and that a percentage of them is CALLA+,
FMC8+, Y29.55+, B7+; none of the SIg+ cells is TdT+.
In normal lymphoid differentiation BA 1 and FMC8 determinants appear at an early stage of
maturation and are retained down to the level of circulating B cells, LeBien et al. (1981). The
reactivity of these two markers with HLA-DR+/SIg+ fetal cells is therefore not unexpected. B2
shows a similar reactivity in that it stains 100% of fetal B cells. We also found that a large proportion
of SIg- fetal bone marrow cells (FACS separated) are BAI+, FMC8+, B2+ (D. Delia, personal
observation) some of which with a myeloid morphology. The remaining probably representing the
B cell precursors. In adult bone marrow B2 labels approximately the same percentage of cells
(6070%) (Mittler et al., 1983) as in fetal bone marrow.
OKB7 reacts in normal peripheral blood with a percentage of B cells and with about 10% of
bone marrow cells (Mittler et al., 1983). In fetal tissues it has exhibited a strong reactivity with spleen
B cells though, occasionally it has bound (weakly) to bone marrow B cells.
The OKB7 differential tissue reactivity has been paralleled by that ofTU22 (the anti-HLA-DC)
which, on the whole reflect distinct B cell maturation stages.
Serological studies on the cellular expression of MHC class II antigens by the haemopoietic
system have shown that DC have a more restricted distribution than DR molecules; HLA-DC
molecules are found in adult peripheral blood B cells (Navarrete et al., 1981), but not on precursor
cells. During normal B-cell ontogeny DC molecules are gained when the cells reach the pre-B level
ofmaturation (Cyt.IgM+, SIg-) (Newman et al., 1983) though leukaemic cell studies would suggest
that the acquisition of DC molecules can occur at a later stage, since some chronic lymphocytic
leukaemias of B cell type are HLA-DC- (Guy & Heyningen, 1983). Not all B cells reacted with
Y29.55, as evident from Table 3, thus suggesting the existence of at least two B cell subsets; Y29.55
recognizes the majority of cells from secondary lymphoid organs, from B cell malignancies and a
minority of peripheral blood B lymphocytes (Forster et al., 1982; Gudat et al., 1981). In agreement
with a previous report (Bonati et al., 1983) we found nuclear TdT+ cells in liver and bone marrow
and only rarely in spleen. The expression of TdT is, in normal B cell maturation, confined to the
CALLA+, HLA-DR+, SIg- cells and it is lost when the cells acquire cytoplasmic IgM (Gathings,
Lawton & Cooper, 1977); circulating and sessile B cells are TdT . Our results show that none of the
SIg+, Y29.55+ cells is TdT+. Given the fact that a percentage of these SIg+ cells is also CALLA+, it
follows that all the SIg+/CALLA+ cells are TdT-. Taken together our data show that during fetal
life B cells retain the CALL antigen and display many of the phenotypic characteristics of mature B
cells, moreover the lack of or very weak reactivity of B7 and TU22 with bone marrow B cells, as
opposed to their strong binding with spleen B cells is suggestive of two distinct discrete stages of
maturation of which the bone marrow B cells reflect the early stage.
Finally, the existance of CALLA+ normal B cells indicates that the CALLA+ subgroup of B
non-Hodgkin's lymphomas do not express this molecule aberrantly: more likely, these cells arise
from normal B cell counterparts that exist in extremely (so far undetected) rare numbers in
lymphoid organs of infants and adults but in large numbers in fetal life.
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Fig. 2. HLA-DR and SIg on CALLA+ enriched fractions. Bone marrow and spleen Vil-Al + mononuclear cells
sorted out with the FACS were restained and re-analysed as described in Materials and Methods. FACS dot
plots ofCALLA+ bone marrow (top panel) and spleen (bottom panel) cells counterstained for HLA-DR (a), (c)
and SIg (b) (d). It can be seen that the majority ofCALLA+ cells is HLA-DR + in both tissues; however, only a
small proportion ofthem is SIg+ in the bone marrow in contrast to the spleen where they are all SIg+. It can be
seen that the bone marrow B cells are smaller than those ofthe spleen. Horizontal axis: light scattering (cell size).
Vertical axis: fluorescence intensity.
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